HORMONE RECEPTOR-POSITIVE / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cheaper generic breast cancer drug put to the test
Disease control OngoingThis study compares the brand-name drug Ibrance (palbociclib) with a local generic version in 100 Iraqi women with stage IV hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the generic works just as well and is as safe as the brand. Patients take the …
Matched conditions: HORMONE RECEPTOR-POSITIVE / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Sponsor: Al-Mustansiriyah University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Hope for advanced breast cancer: new combo targets resistant tumors
Disease control OngoingThis study tests whether adding abemaciclib to fulvestrant can slow or stop the growth of a common type of advanced breast cancer (HR+, HER2-) that has worsened after initial treatment. About 368 participants will receive either the drug combo or a placebo plus fulvestrant. The g…
Matched conditions: HORMONE RECEPTOR-POSITIVE / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC